Communications Biology (Oct 2024)

Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

  • Belamy B. Cheung,
  • Ritu Mittra,
  • Jayne Murray,
  • Qian Wang,
  • Janith A. Seneviratne,
  • Mukesh Raipuria,
  • Iris Poh Ling Wong,
  • David Restuccia,
  • Andrew Gifford,
  • Alice Salib,
  • Selina Sutton,
  • Libby Huang,
  • Parisa Vahidi Ferdowsi,
  • Joanna Tsang,
  • Eric Sekyere,
  • Chelsea Mayoh,
  • Lin Luo,
  • Darren L. Brown,
  • Jennifer L. Stow,
  • Shizhen Zhu,
  • Richard J. Young,
  • Benjamin J. Solomon,
  • Stephane Chappaz,
  • Benjamin Kile,
  • Andrew Kueh,
  • Marco J. Herold,
  • Douglas J. Hilton,
  • Tao Liu,
  • Murray D. Norris,
  • Michelle Haber,
  • Daniel R. Carter,
  • Michael W. Parker,
  • Glenn M. Marshall

DOI
https://doi.org/10.1038/s42003-024-06899-8
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 13

Abstract

Read online

Abstract MYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders which had lost tumorigenesis. Sequencing of the mutant mouse genomes identified the Ring Finger Protein 121 (RNF121 WT ) gene mutated to RNFM158R associated with heritable loss of tumorigenicity. While the RNF121WT protein localised predominantly to the cis-Golgi Complex, the RNF121 M158R mutation in Helix 4 of its transmembrane domain caused reduced RNF121 protein stability and absent Golgi localisation. RNF121WT expression markedly increased during TH-MYCN tumorigenesis, whereas hemizygous RNF121 WT gene deletion reduced TH-MYCN tumorigenicity. The RNF121WT-enhanced growth of MYCN-amplified neuroblastoma cells depended on RNF121WT transmembrane Helix 5. RNF121WT directly bound MYCN protein and enhanced its stability. High RNF121 mRNA expression associated with poor prognosis in human neuroblastoma tissues and another MYC-driven malignancy, laryngeal cancer. RNF121 is thus an essential oncogenic cofactor for MYCN and a target for drug development.